IP Library Granted Patent US 10,071,056
Granted Patent B2
US 10,071,056 · App. 15/046,817 · Granted Sep 11, 2018

Cancer cell targeting using nanoparticles

Inventors: Stephen E. Zale (Hopkinton, MA); Mir Mukkaram Ali (Woburn, MA)
Assignee: Pfizer Inc.
A61K9/1647A61K9/146A61K9/5153A61K9/5192A61K31/136A61K31/197A61K31/337A61K31/704A61K47/34A61K47/542A61K47/60A61K47/6935A61K47/6937B82Y5/00C07C275/16C07C275/24C08G63/664C08G63/6852C08G63/6922Y10S977/904Y10S977/905Y10S977/906Y10S977/911Y10S977/915
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,071,056
App. No.
15/046,817
Granted
Sep 11, 2018
Kind
B2
Abstract

The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Claims (12)

1. A method of preparing a stealth nanoparticle having a ratio of ligand-bound polymer to non-functionalized polymer effective for the treatment of prostate cancer, comprising the steps of: (a) providing an anti-cancer agent; (b) providing a first polymer; (c) providing a low-molecular weight PSMA ligand; (d) reacting the first polymer with the low-molecular weight PSMA ligand to form a ligand-bound polymer; and (e) mixing the ligand-bound polymer with a second polymer, wherein the second polymer is non-functionalized, and the anti-cancer agent, thereby forming the stealth nanoparticle,

wherein the ligand-bound polymer is:

wherein

R 1 and R 3 are alkyl groups;

R 2 is an ester group or amide linkage;

X+Y=20 to 1720; and

Z=25 to 455.

2. The method of claim 1 , wherein the second polymer comprises a block copolymer of two or more polymers.

3. The method of claim 2 , wherein the second polymer is a diblock copolymer of (i) PLGA and PEG or (ii) PLA and PEG.

4. The method of claim 1 , wherein the anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel, mitoxandrone, doxorubicin, gemcitabine, 5-fluorouracil, daunorubicin or 9-dihydrotaxol.

5. The method of claim 4 , wherein the anti-cancer agent is paclitaxel, docetaxel or dihydrotaxol.

6. The method of claim 1 , wherein the nanoparticle has a diameter of 80 nm to 200 nm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2016
From: BIND THERAPEUTICS, INC.
To: PFIZER INC.
Reel/Frame 040707/0868 →
Continuity (6)
Continuation 14182557 · Feb 18, 2014
Continuation 13595592 · Aug 27, 2012
Continuation 13109425 · May 17, 2011
Continuation 12059496 · Mar 31, 2008
Provisional Application 60976197 · Sep 28, 2007
Related Publication 20160367481A1 · Dec 22, 2016